Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976218 | 0.85 | HDAC6 (0.62) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL1161248 | 0.85 | HDAC6 (0.62) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL8861233 | 0.85 | HDAC6 (0.62) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL28506236 | 0.83 | HDAC6 (0.64) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL28490940 | 0.82 | HDAC6 (0.63) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL6837735 | 0.82 | KDM4E (0.69) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL28514107 | 0.82 | HDAC6 (0.63) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL981898 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL11331858 | 0.81 | HDAC6 (0.58) | KDM4EALDH1A1MAPK1HPGDLMNA | |
| SCHEMBL28499652 | 0.81 | HDAC6 (0.58) | KDM4EALDH1A1MAPK1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4181724-A | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | claimed |
| CN-110117260-B | Preparation method of 3-alkyl quinoxaline-2 (1H) -ketone compound | 湖南科技学院 | 2020-12-25 | — | — | CN | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| EP-1620409-A1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096780-A1 | QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096780-A1 | QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | KDM4E 1645/4885ALDH1A1 1096/4885MAPK1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.